"The U.S. Food and Drug Administration yesterday approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).
Vimizim Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Vimizim (elosulfase alfa) Injection is a form of an enzyme used for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). Common side effects include fever, vomiting, headache, nausea, abdominal pain, chills, and fatigue.
The recommended dose of Vimizim is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week. Vimizim may interact with other drugs. Tell your doctor all medications and supplements you use.
There is a Morquio A Registry that collects data on pregnant and breastfeeding women with MPS IVA who are treated with Vimizim. During pregnancy, Vimizim should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Vimizim (elosulfase alfa) Injection, Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Vimizim FDA Prescribing Information: Side Effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The following serious adverse reactions are described below and elsewhere in the labeling:
The most common adverse reactions ( ≥ 10%) observed across pre-marketing clinical trials were similar in type and frequency as those observed in the placebo-controlled trial (see Table1). The acute reactions requiring intervention were managed by either temporarily interrupting or discontinuing infusion, and administering additional antihistamine, antipyretics, or corticosteroids.
Clinical Trials Experience
A 24-week, randomized, double-blind, placebo-controlled clinical trial of Vimizim was conducted in 176 patients with MPS IVA, ages 5 to 57 years old. Approximately half of the patients (49%) were male. Of the 176 patients, 65% were White, 23% Asian, 3% Black, and 10% Other race. The majority of patients (78%) were non-Hispanic. Patients were randomized to three treatment groups: Vimizim 2 mg/kg once per week (n=58), Vimizim 2 mg/kg once every other week (n=59), or placebo (n=59). All patients were treated with antihistamines prior to each infusion.
Table 1 summarizes the most common adverse reactions that occurred in the placebo-controlled trial with an incidence of ≥ 10% in patients treated with Vimizim 2 mg/kg once per week and with a higher incidence than in the placebo-treated patients.
Table 1: Adverse Reactions That Occurred in the
Placebo-Controlled Trial in At Least 10% of Patients in the Vimizim 2 mg/kg
Once Per Week Group and with a Higher Incidence than in the Placebo Group
|Adverse Reaction||Vimizim 2 mg/kg once per week
|Pyrexia||19 (33%)||8 (14%)|
|Vomiting||18 (31%)||4 (7%)|
|Headache||15 (26%)||9 (15%)|
|Nausea||14 (24%)||4 (7%)|
|Abdominal pain||12 (21%)||1 (1.7%)|
|Chills||6 (10.3%)||1 (1.7%)|
|Fatigue||6 (10.3%)||2 (3.4%)|
An open-label extension trial was conducted in 173 patients who completed the placebo-controlled trial [see Clinical Studies]. No new adverse reactions were reported.
As with all therapeutic proteins, there is potential for immunogenicity. All patients treated with Vimizim 2 mg/kg once per week in the placebo-controlled trial developed anti-drug antibodies by Week 4. Anti-drug antibody titers were sustained or increased for the duration of Vimizim treatment. Because all patients developed anti-drug antibodies, associations between antibody titers and reductions in treatment effect or the occurrence of anaphylaxis or other hypersensitivity reactions could not be determined.
All patients treated with Vimizim 2 mg/kg once per week tested positive for neutralizing antibodies capable of inhibiting the drug from binding to the mannose-6-phosphate receptor at least once during the trial. Binding to this receptor is required for Vimizim to be taken into cells where it is active. Neutralizing antibody titers were not determined in the patients. Therefore, the possibility of an association between neutralizing antibody titer and treatment effect cannot be assessed.
Assessment of the incidence of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Vimizim with the incidence of antibodies to other products may be misleading.
Read the entire FDA prescribing information for Vimizim (Elosulfase Alfa Injection for Intravenous Use)
Additional Vimizim Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.